Low rates of contrast-induced nephropathy in patients with diabetes mellitus and chronic kidney disease: PREDICT study

Analysis by V. Matarese


The PREDICT study [1] is the latest addition to a body of evidence on the renal safety of iodinated contrast agents.  In this randomized controlled trial (RCT), researchers from universities and private clinics in the US and China did a head-to-head comparison of intravenously administered Iodixanol-320 and Iopamidol-370, two well-studied nonionic contrast agents.  Iodixanol is iso-osmolar to blood (290 mOsm/kg H20, 320 mgI/ml) while iopamidol is hyperosmolar to blood (796 mOsm/kg H20, 370 mgI/ml); however, iopamidol is a low-osmolar contrast medium due to the existence of contrast media of even greater osmolality.
This content is only available to registered users. Log in or create a new account for free.
Lost Password

Log in with your credentials

Forgot your details?